Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

BGLC

BioNexus Gene Lab Corp

Apr 30 • 10:27AM ET

2.10

+0.04 1.94 %

Basic Materials • Specialty Chemicals • Malaysia • Nano • NASD

Peers: ILMN GH EXAS QGEN MYGN CRSP FATE FLGT CGEN EDIT

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.61	Insider Own	35.59%	Shs Outstand	2.42M	Perf Week	-5.83%
Market Cap	5.08M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	1.56M	Perf Month	-1.90%
Enterprise Value	1.22M	PEG	-	EPS next Q	-	Inst Own	1.98%	Short Float	0.64%	Perf Quarter	-20.75%
Income	-2.98M	P/S	0.68	EPS this Y	-	Inst Trans	17.37%	Short Ratio	0.74	Perf Half Y	-59.54%
Sales	7.42M	P/B	0.59	EPS next Y	-	ROA	-30.32%	Short Interest	0.01M	Perf YTD	-46.84%
Book/sh	3.56	P/C	1.26	EPS next 5Y	-	ROE	-35.24%	52W High	15.60 -86.54%	Perf Year	-26.32%
Cash/sh	1.67	P/FCF	-	EPS past 3/5Y	-86.65% -	ROIC	-34.18%	52W Low	1.92 9.37%	Perf 3Y	-94.67%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-12.09% -8.20%	Gross Margin	14.23%	Volatility	1.81% 2.63%	Perf 5Y	-99.12%
Dividend TTM	-	EV/Sales	0.16	EPS Y/Y TTM	-80.87%	Oper. Margin	-42.54%	ATR (14)	0.09	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	9.16	Sales Y/Y TTM	-21.93%	Profit Margin	-40.20%	RSI (14)	39.85	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	10.46	EPS Q/Q	-169.73%	SMA20	-4.87%	Beta	2.21	Target Price	-
Payout	-	Debt/Eq	0.02	Sales Q/Q	-80.83%	SMA50	-10.45%	Rel Volume	0.04	Prev Close	2.06
Employees	16	LT Debt/Eq	0.01	Earnings	-	SMA200	-48.34%	Avg Volume	13.38K	Price	2.10
IPO	Sep 16, 2020	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	100	Change	1.94%

Mar-11-26 08:45AM	BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuard MRD Platform (GlobeNewswire)
Feb-23-26 08:30AM	BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman (GlobeNewswire)
Jan-28-26 09:00AM	BioNexus Launches Regional Deployment of VitaGuard MRD Infrastructure; Positioned to Challenge Legacy Oncology Platforms Across ASEAN's Multi-Billion Dollar Market (GlobeNewswire)
Dec-03-25 08:45AM	BioNexus Gene Lab Corp. Completes Strategic Investment in Fidelion Diagnostics; Secures 15% Equity Stake in Global AI-Oncology Platform and Exclusive Southeast Asian Rights for VitaGuard (GlobeNewswire)
Dec-02-25 08:05AM	BioNexus Gene Lab Corp. (Nasdaq: BGLC) Secures $500 Million Equity Facility From ARC Group International to Support Expansion of Precision Diagnostics, CDMO Operations, and Therapeutic Commercialization (GlobeNewswire)
08:00AM	Loading…
Dec-01-25 08:00AM	BioNexus Gene Lab Corp. (Nasdaq: BGLC) and Fidelion Diagnostics Execute Exclusive Southeast Asia License for VitaGuard MRD Platform as Part of Strategic Alliance with Tongshu Gene (GlobeNewswire)
Nov-12-25 08:00AM	BioNexus Gene Lab Corp. (Nasdaq: BGLC) Announces Strategic Agreements with Fidelion Diagnostics for Southeast Asia MRD Commercialization (GlobeNewswire) -6.02%
Nov-10-25 08:00AM	BioNexus Gene Lab Corp. Files $100 Million Shelf Registration and Establishes $20 Million At-the-Market Program to Advance Strategic Growth Opportunities (GlobeNewswire)
Oct-20-25 08:00AM	BioNexus Gene Lab Corp Signs Strategic Partnership Term Sheet with BirchBioMed Inc. (GlobeNewswire)
Jul-30-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +60.99%
08:00AM	BioNexus Gene Lab Corp. and Fidelion Diagnostics Announce Landmark Alliance-Touted as a new "DeepSeek Moment" in Precision Oncology (GlobeNewswire)
Apr-30-25 11:25AM	BioNexus Gene Lab Corp. Regains Nasdaq Compliance, Signaling Strategic Stability and Growth Readiness (GlobeNewswire)
Apr-15-25 11:00AM	BioNexus Gene Lab Corp. Files 2024 Annual Report Highlighting Strategic Innovation, Operational Resilience, and Growth Trajectory (GlobeNewswire) +14.22%
Mar-08-25 11:10AM	Bionexus Gene Lab enters partnership with ML Tech (TipRanks)
Mar-07-25 11:00AM	BioNexus Gene Lab Corp and ML Tech Partner to Enhance Ethereum-focused Treasury Strategy (GlobeNewswire) +6.96%
11:00AM	Loading…
Mar-05-25 11:00AM	BioNexus Gene Lab Corp. Announces Board Approval of Ethereum Treasury Strategy and Release of Strategic Whitepaper (GlobeNewswire)
Sep-25-24 11:31AM	BioNexus Gene Lab Corporation announces entry into Biogas Sector via Teaming Agreement with Protech Builders Sdn. Bhd. (GlobeNewswire)
Sep-13-24 12:05PM	BioNexus Gene Lab Corp. Signs Strategic Outsourcing Agreement with VITARRAY Global Pte. Ltd. (GlobeNewswire)
Sep-12-24 01:23PM	BioNexus Gene Lab Corp. Signs Strategic Partnership MOU with Shenzhen Rongguang Group to Advance Cancer Screening, Precision Medicine, and Preventative Healthcare Solutions (GlobeNewswire) +8.36%
Sep-11-24 11:05AM	BioNexus Gene Lab Corp Announces New Business Developments for Subsidiary Chemrex with Investment in High-Quality Color Paste Production (GlobeNewswire)
Aug-27-24 11:35AM	BioNexus Gene Lab Corp. Announces Successful Securities Commission of Malaysia (MyCIF) Co-Investment in Ascension Innovation Sdn Bhd (GlobeNewswire)
Aug-26-24 12:15PM	BioNexus Gene Lab Corp. Completes Strategic RM 1 Million Investment in Ascension Innovation Sdn Bhd (GlobeNewswire)
Jul-15-24 07:35AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
Apr-19-24 08:58AM	Why Is BioNexus Gene Lab (BGLC) Stock Down 27% Today? (InvestorPlace) -29.32%
Apr-18-24 02:52PM	BioNexus Gene Lab Corp. Agrees to Invest RM 1.2 million in Ascension Innovation (AISB) to Advance Digital Health Innovation through AI adoption in Healthcare (GlobeNewswire) +34.00%
Jul-24-23 11:30AM	BioNexus Gene Lab Corp. Announces Closing of $5.75 Million Public Offering and Full Exercise of Over-Allotment Option and Uplisting to the Nasdaq Capital Market (GlobeNewswire) -10.08%
Jul-20-23 01:29PM	BioNexus Gene Lab Corp. Announces Pricing of $5 Million Public Offering and Uplisting to the Nasdaq Capital Market (GlobeNewswire) -55.40%

BioNexus Gene Lab Corp. operates as a holding company, which engages in the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries. It is also involved in the development of liquid biopsy tests for the early detection of biomarkers that are linked to diseases. It operates through the BioNexus Malaysia and Chemrex segments. The company was founded by Liew Choong-Chin on May 12, 2017 and is headquartered in Kuala Lumpur, Malaysia.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BGLC

BioNexus Gene Lab Corp

Upgrade your Finviz experience